*	OR T1 T2
R1	Has_multiplier Arg1:T1 Arg2:T3	
*	OR T5 T6
R2	Has_temporal Arg1:T1 Arg2:T9	
R3	AND Arg1:T7 Arg2:T5	
R4	Has_temporal Arg1:T7 Arg2:T10	
*	OR T11 T12
R5	Has_multiplier Arg1:T14 Arg2:T13	
R6	Has_multiplier Arg1:T14 Arg2:T15	
R7	Has_temporal Arg1:T14 Arg2:T16	
R8	Has_multiplier Arg1:T18 Arg2:T17	
R9	Has_multiplier Arg1:T18 Arg2:T19	
R10	Has_temporal Arg1:T18 Arg2:T20	
*	OR T21 T22
R11	Has_qualifier Arg1:T23 Arg2:T21	
R12	Has_temporal Arg1:T23 Arg2:T24	
*	OR T27 T29 T28
R13	Has_temporal Arg1:T27 Arg2:T30	
R14	Has_temporal Arg1:T32 Arg2:T33	
R15	Has_temporal Arg1:T35 Arg2:T36	
R16	Has_qualifier Arg1:T35 Arg2:T34	
*	OR T37 T38
R17	Has_mood Arg1:T41 Arg2:T40	
R18	Subsumes Arg1:T37 Arg2:T41	
R19	Has_temporal Arg1:T43 Arg2:T44	
R20	Has_negation Arg1:T43 Arg2:T42	
R21	AND Arg1:T46 Arg2:T47	
R22	Has_mood Arg1:T46 Arg2:T45	
R23	Has_value Arg1:T50 Arg2:T49	
R24	Has_negation Arg1:T50 Arg2:T48	
R25	Has_value Arg1:T52 Arg2:T51	
R26	Has_qualifier Arg1:T54 Arg2:T53	
R27	AND Arg1:T55 Arg2:T54	
R28	multi Arg1:T58 Arg2:T59	
R29	multi Arg1:T57 Arg2:T58	
R30	Has_index Arg1:T56 Arg2:T57	
R31	Has_temporal Arg1:T55 Arg2:T56	
*	OR T60 T61
*	OR T60 T64 T65 T63
R32	Has_temporal Arg1:T60 Arg2:T62	
R33	Has_qualifier Arg1:T66 Arg2:T68	
R34	Has_index Arg1:T69 Arg2:T70	
R35	Has_temporal Arg1:T66 Arg2:T69	
R36	Has_value Arg1:T71 Arg2:T72	
R37	Has_negation Arg1:T71 Arg2:T73	
R38	AND Arg1:T74 Arg2:T75	
R39	Has_negation Arg1:T78 Arg2:T79	
*	OR T71 T78 T75
R40	Has_negation Arg1:T75 Arg2:T76	
T1	Drug 21 35	anti-TNF agent
T2	Drug 39 44	DMARD
T3	Multiplier 4 17	dose increase
T5	Drug 81 95	anti-TNF agent
T6	Drug 99 104	DMARD
T7	Procedure 71 77	change
T9	Temporal 45 65	in the last 6 months
T10	Temporal 105 125	in the last 6 months
T11	Drug 150 159	golimumab
T12	Drug 163 175	certolizumab
T13	Multiplier 190 208	greater than 10 mg
T14	Drug 212 222	prednisone
T15	Multiplier 239 244	daily
T16	Temporal 245 265	in the last 6 months
T17	Multiplier 280 297	greater than 5 mg
T18	Drug 301 311	prednisone
T19	Multiplier 328 333	daily
T20	Temporal 334 354	in the last 3 months
T21	Qualifier 369 382	intramuscular
T22	Qualifier 386 397	intravenous
T23	Drug 398 413	corticosteroids
T24	Temporal 414 434	in the last 6 months
T25	Condition 439 441	RA
T27	Drug 465 473	anakinra
T28	Drug 475 484	abatacept
T29	Drug 489 500	tocilizumab
T30	Temporal 501 521	in the last 6 months
T32	Drug 536 545	rituximab
T33	Temporal 546 567	in the last 12 months
T34	Qualifier 585 600	investigational
T35	Drug 601 608	RA drug
T36	Temporal 609 629	in the last 6 months
T37	Condition 631 639	Pregnant
T38	Condition 693 702	lactating
T39	Person 703 708	women
T40	Mood 644 654;665 688	anticipate during the study period
T41	Condition 655 664	pregnancy
T42	Negation 710 720	Absence of
T43	Condition 760 778	clinical remission
T44	Temporal 779 800	for the last 6 months
T45	Mood 802 811	Unwilling
T46	Procedure 815 826	discontinue
T47	Drug 827 841	anti-TNF agent
T48	Negation 843 853	Absence of
T49	Value 871 879	negative
T50	Procedure 880 900	tuberculin skin test
T51	Value 902 910	negative
T52	Measurement 911 935	QuantiFERON-TB Gold test
T53	Qualifier 954 960	latent
T54	Condition 961 973	tuberculosis
T55	Procedure 940 949	treatment
T56	Temporal 974 1025	prior to starting treatment with the anti-TNF agent
T57	Reference_point 983 1025	starting treatment with the anti-TNF agent
T58	Procedure 992 1025	treatment with the anti-TNF agent
T59	Drug 1011 1025	anti-TNF agent
T60	Condition 1040 1056	solid malignancy
T61	Condition 1060 1084	non-melanoma skin cancer
T62	Temporal 1085 1108	within the past 5 years
T63	Condition 1128 1136	melanoma
T64	Condition 1140 1151	hematologic
T65	Condition 1155 1185	lymphoproliferative malignancy
T66	Procedure 1231 1247	cancer screening
T68	Qualifier 1215 1230	age-appropriate
T69	Temporal 1248 1276	at the time of randomization
T70	Reference_point 1251 1276	the time of randomization
T71	Measurement 1315 1337	hepatitis B serologies
T72	Value 1306 1314	negative
T73	Negation 1278 1288	Absence of
T74	Procedure 1364 1373	treatment
T75	Condition 1378 1397	chronic hepatitis B
T76	Negation 1339 1349	absence of
T77	Non-representable 1350 1363	completion of
T78	Procedure 1413 1444	suppressive antiviral treatment
T79	Negation 1402 1409	absence
T80	Informed_consent 1446 1480	Unable to provide informed consent
T81	Post-eligibility 1482 1564	Anticipate not being available or able to comply with the schedule of study visits
